WEKO3
アイテム
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
http://hdl.handle.net/10076/0002001075
http://hdl.handle.net/10076/0002001075d2d8e40a-839f-4f5a-8bc2-acaa41112b0c
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
2024DM0902.pdf (1.3 MB)
|
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-12-16 | |||||||||
| タイトル | ||||||||||
| タイトル | Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy | |||||||||
| 言語 | en | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| キーワード | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | immune checkpoint inhibitor | |||||||||
| キーワード | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | small cell lung cancer | |||||||||
| キーワード | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| 主題 | amrubicin | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||||
| 資源タイプ | doctoral thesis | |||||||||
| アクセス権 | ||||||||||
| アクセス権 | open access | |||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||
| 著者 |
西村, 正
× 西村, 正
|
|||||||||
| 抄録 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | Adding an immune checkpoint inhibitor to chemotherapy to treat extensive-stage small cell lung cancer is effective. However, there are no reports of an effective second-line treatment in patients previously treated with chemotherapy and immune checkpoint inhibitors as a first-line treatment. Here, we assessed the efficacy and safety of amrubicin as a second-line treatment for extensive-stage small cell lung cancer after chemotherapy and immune checkpoint inhibitor combination therapy. The study enrolled 150 patients with extensive-stage small cell lung cancer. The efficacy and the incidence of adverse events were compared between patients previously treated with immune checkpoint inhibitors and patients without previous immune checkpoint inhibitor treatment. One hundred and twenty-three patients were eligible. There was no difference in objective response rate, time-to-treatment failure, progression-free survival, and overall survival between both groups. The incidence of adverse events was similar in both treatment groups. Pretreatment with immune checkpoint inhibitors was not associated with an increase in amrubicin-related adverse events. This study shows that the efficacy of amrubicin in extensive-stage small cell lung cancer remains unchanged irrespective of previous treatment with immune checkpoint inhibitors. Amrubicin-related adverse events did not increase in patients previously treated with immune checkpoint inhibitors. | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | 本文/Department of Pulmonary Medicine, Mie Chuo Medical Center, Tsu 514-1101, Mie, Japan | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | 10p | |||||||||
| 書誌情報 |
発行日 2024-09-25 |
|||||||||
| DOI | ||||||||||
| 識別子タイプ | DOI | |||||||||
| 関連識別子 | 10.3390/cancers14163953 | |||||||||
| フォーマット | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | application/pdf | |||||||||
| 出版者 | ||||||||||
| 出版者 | 三重大学 | |||||||||
| 出版者（ヨミ） | ||||||||||
| ミエダイガク | ||||||||||
| 学位名 | ||||||||||
| 学位名 | 博士(医学) | |||||||||
| 学位授与機関 | ||||||||||
| 学位授与機関識別子Scheme | kakenhi | |||||||||
| 学位授与機関識別子 | 14101 | |||||||||
| 学位授与機関名 | 三重大学 | |||||||||
| 学位授与年月日 | ||||||||||
| 学位授与年月日 | 2024-09-25 | |||||||||
| 学位授与番号 | ||||||||||
| 学位授与番号 | 甲医学第2277号 | |||||||||
| ノート | ||||||||||
| 資源タイプ（三重大） | ||||||||||
| Doctoral Dissertation / 博士論文 | ||||||||||
